nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—PDGFRA—brain cancer	0.324	0.663	CbGaD
Nilotinib—CYP2C9—brain cancer	0.164	0.337	CbGaD
Nilotinib—UGT1A1—Etoposide—brain cancer	0.0303	0.191	CbGbCtD
Nilotinib—CYP2D6—Lomustine—brain cancer	0.0234	0.147	CbGbCtD
Nilotinib—ABCG2—Carboplatin—brain cancer	0.0198	0.125	CbGbCtD
Nilotinib—CYP2D6—Hydroxyurea—brain cancer	0.0177	0.112	CbGbCtD
Nilotinib—CYP3A4—Temozolomide—brain cancer	0.0175	0.11	CbGbCtD
Nilotinib—ABCG2—Etoposide—brain cancer	0.0166	0.105	CbGbCtD
Nilotinib—CYP3A4—Lomustine—brain cancer	0.0149	0.0938	CbGbCtD
Nilotinib—CYP2C8—Etoposide—brain cancer	0.00886	0.0559	CbGbCtD
Nilotinib—ABCB1—Etoposide—brain cancer	0.006	0.0378	CbGbCtD
Nilotinib—CYP3A4—Etoposide—brain cancer	0.00359	0.0227	CbGbCtD
Nilotinib—Ponatinib—PDGFRA—brain cancer	0.00226	0.519	CrCbGaD
Nilotinib—Imatinib—PDGFRA—brain cancer	0.00139	0.319	CrCbGaD
Nilotinib—Imatinib—CYP2C9—brain cancer	0.000706	0.162	CrCbGaD
Nilotinib—EPHA6—head—brain cancer	0.000411	0.0044	CbGeAlD
Nilotinib—MAPK11—cerebellum—brain cancer	0.000408	0.00437	CbGeAlD
Nilotinib—CA14—telencephalon—brain cancer	0.000407	0.00436	CbGeAlD
Nilotinib—HCK—pituitary gland—brain cancer	0.000407	0.00436	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—brain cancer	0.000405	0.00434	CbGeAlD
Nilotinib—ABL2—pituitary gland—brain cancer	0.000404	0.00433	CbGeAlD
Nilotinib—EPHB4—telencephalon—brain cancer	0.000397	0.00425	CbGeAlD
Nilotinib—BRAF—midbrain—brain cancer	0.000394	0.00422	CbGeAlD
Nilotinib—EPHA3—central nervous system—brain cancer	0.000393	0.00421	CbGeAlD
Nilotinib—HCK—medulla oblongata—brain cancer	0.000393	0.00421	CbGeAlD
Nilotinib—CA4—hindbrain—brain cancer	0.000387	0.00414	CbGeAlD
Nilotinib—LYN—endocrine gland—brain cancer	0.000384	0.00411	CbGeAlD
Nilotinib—EPHB3—spinal cord—brain cancer	0.000381	0.00408	CbGeAlD
Nilotinib—TEK—telencephalon—brain cancer	0.00038	0.00407	CbGeAlD
Nilotinib—EPHA4—gonad—brain cancer	0.000379	0.00406	CbGeAlD
Nilotinib—LYN—head—brain cancer	0.000379	0.00406	CbGeAlD
Nilotinib—MAPK8—central nervous system—brain cancer	0.000375	0.00401	CbGeAlD
Nilotinib—EPHA6—central nervous system—brain cancer	0.000375	0.00401	CbGeAlD
Nilotinib—EPHB2—brain—brain cancer	0.000372	0.00399	CbGeAlD
Nilotinib—EPHA4—pituitary gland—brain cancer	0.00037	0.00396	CbGeAlD
Nilotinib—MAPK8—cerebellum—brain cancer	0.000366	0.00392	CbGeAlD
Nilotinib—CA3—pituitary gland—brain cancer	0.000365	0.00391	CbGeAlD
Nilotinib—EPHB6—telencephalon—brain cancer	0.000363	0.00389	CbGeAlD
Nilotinib—HCK—midbrain—brain cancer	0.000359	0.00384	CbGeAlD
Nilotinib—EPHA4—medulla oblongata—brain cancer	0.000357	0.00382	CbGeAlD
Nilotinib—EPHA8—brain—brain cancer	0.000357	0.00382	CbGeAlD
Nilotinib—TIE1—head—brain cancer	0.000356	0.00381	CbGeAlD
Nilotinib—CA7—midbrain—brain cancer	0.000351	0.00376	CbGeAlD
Nilotinib—HCK—spinal cord—brain cancer	0.00035	0.00375	CbGeAlD
Nilotinib—MAP2K5—brainstem—brain cancer	0.00035	0.00375	CbGeAlD
Nilotinib—LYN—central nervous system—brain cancer	0.000346	0.0037	CbGeAlD
Nilotinib—PDGFRA—telencephalon—brain cancer	0.000344	0.00369	CbGeAlD
Nilotinib—MAPK14—pituitary gland—brain cancer	0.000341	0.00365	CbGeAlD
Nilotinib—FGR—pituitary gland—brain cancer	0.00034	0.00364	CbGeAlD
Nilotinib—EPHB3—head—brain cancer	0.000339	0.00363	CbGeAlD
Nilotinib—MAPK11—brain—brain cancer	0.000332	0.00355	CbGeAlD
Nilotinib—CDC42BPB—brain—brain cancer	0.000329	0.00352	CbGeAlD
Nilotinib—TIE1—central nervous system—brain cancer	0.000325	0.00348	CbGeAlD
Nilotinib—EPHB4—pituitary gland—brain cancer	0.000323	0.00346	CbGeAlD
Nilotinib—CA2—hindbrain—brain cancer	0.000321	0.00343	CbGeAlD
Nilotinib—CA14—medulla oblongata—brain cancer	0.00032	0.00343	CbGeAlD
Nilotinib—CA12—telencephalon—brain cancer	0.000318	0.0034	CbGeAlD
Nilotinib—TIE1—cerebellum—brain cancer	0.000318	0.0034	CbGeAlD
Nilotinib—EPHA2—pituitary gland—brain cancer	0.000317	0.0034	CbGeAlD
Nilotinib—HCK—endocrine gland—brain cancer	0.000315	0.00338	CbGeAlD
Nilotinib—EPHB4—medulla oblongata—brain cancer	0.000312	0.00334	CbGeAlD
Nilotinib—EPHA3—brain—brain cancer	0.000312	0.00334	CbGeAlD
Nilotinib—HCK—head—brain cancer	0.000311	0.00333	CbGeAlD
Nilotinib—MAP2K5—telencephalon—brain cancer	0.00031	0.00333	CbGeAlD
Nilotinib—KIT—brainstem—brain cancer	0.00031	0.00332	CbGeAlD
Nilotinib—TEK—pituitary gland—brain cancer	0.000309	0.00331	CbGeAlD
Nilotinib—EPHB3—central nervous system—brain cancer	0.000309	0.00331	CbGeAlD
Nilotinib—BRAF—cerebellum—brain cancer	0.000304	0.00326	CbGeAlD
Nilotinib—CSF1R—telencephalon—brain cancer	0.000303	0.00325	CbGeAlD
Nilotinib—EPHB3—cerebellum—brain cancer	0.000302	0.00324	CbGeAlD
Nilotinib—TEK—medulla oblongata—brain cancer	0.000298	0.0032	CbGeAlD
Nilotinib—EPHA6—brain—brain cancer	0.000297	0.00319	CbGeAlD
Nilotinib—MAPK8—brain—brain cancer	0.000297	0.00319	CbGeAlD
Nilotinib—EPHB6—pituitary gland—brain cancer	0.000296	0.00317	CbGeAlD
Nilotinib—CA6—head—brain cancer	0.000295	0.00316	CbGeAlD
Nilotinib—MAPK14—spinal cord—brain cancer	0.000293	0.00314	CbGeAlD
Nilotinib—CA14—midbrain—brain cancer	0.000292	0.00313	CbGeAlD
Nilotinib—PDGFRA—gonad—brain cancer	0.000287	0.00308	CbGeAlD
Nilotinib—EPHA4—endocrine gland—brain cancer	0.000286	0.00307	CbGeAlD
Nilotinib—CA14—spinal cord—brain cancer	0.000285	0.00306	CbGeAlD
Nilotinib—EPHB6—medulla oblongata—brain cancer	0.000285	0.00306	CbGeAlD
Nilotinib—EPHB4—midbrain—brain cancer	0.000285	0.00305	CbGeAlD
Nilotinib—HCK—central nervous system—brain cancer	0.000284	0.00304	CbGeAlD
Nilotinib—CA3—endocrine gland—brain cancer	0.000283	0.00303	CbGeAlD
Nilotinib—EPHA4—head—brain cancer	0.000283	0.00303	CbGeAlD
Nilotinib—CA3—head—brain cancer	0.000279	0.00299	CbGeAlD
Nilotinib—EPHB4—spinal cord—brain cancer	0.000278	0.00298	CbGeAlD
Nilotinib—ABL2—cerebellum—brain cancer	0.000276	0.00296	CbGeAlD
Nilotinib—KIT—telencephalon—brain cancer	0.000275	0.00295	CbGeAlD
Nilotinib—LYN—brain—brain cancer	0.000275	0.00294	CbGeAlD
Nilotinib—TEK—midbrain—brain cancer	0.000273	0.00292	CbGeAlD
Nilotinib—CA7—cerebellum—brain cancer	0.000272	0.00291	CbGeAlD
Nilotinib—CA9—endocrine gland—brain cancer	0.000271	0.0029	CbGeAlD
Nilotinib—MAP4K1—brain—brain cancer	0.00027	0.0029	CbGeAlD
Nilotinib—ABL1—brainstem—brain cancer	0.00027	0.00289	CbGeAlD
Nilotinib—PDGFRB—telencephalon—brain cancer	0.000269	0.00288	CbGeAlD
Nilotinib—TEK—spinal cord—brain cancer	0.000266	0.00285	CbGeAlD
Nilotinib—MAPK14—endocrine gland—brain cancer	0.000264	0.00283	CbGeAlD
Nilotinib—FGR—endocrine gland—brain cancer	0.000263	0.00282	CbGeAlD
Nilotinib—MAPK14—head—brain cancer	0.000261	0.00279	CbGeAlD
Nilotinib—EPHB6—midbrain—brain cancer	0.000261	0.00279	CbGeAlD
Nilotinib—FGR—head—brain cancer	0.00026	0.00278	CbGeAlD
Nilotinib—EPHA4—central nervous system—brain cancer	0.000258	0.00277	CbGeAlD
Nilotinib—TIE1—brain—brain cancer	0.000258	0.00276	CbGeAlD
Nilotinib—CA3—central nervous system—brain cancer	0.000255	0.00273	CbGeAlD
Nilotinib—EPHB6—spinal cord—brain cancer	0.000254	0.00272	CbGeAlD
Nilotinib—CSF1R—gonad—brain cancer	0.000253	0.00271	CbGeAlD
Nilotinib—MAP2K5—pituitary gland—brain cancer	0.000253	0.00271	CbGeAlD
Nilotinib—EPHA4—cerebellum—brain cancer	0.000252	0.0027	CbGeAlD
Nilotinib—CA1—telencephalon—brain cancer	0.000252	0.0027	CbGeAlD
Nilotinib—EPHB4—endocrine gland—brain cancer	0.00025	0.00268	CbGeAlD
Nilotinib—BRAF—brain—brain cancer	0.000247	0.00265	CbGeAlD
Nilotinib—CSF1R—pituitary gland—brain cancer	0.000247	0.00264	CbGeAlD
Nilotinib—EPHA2—endocrine gland—brain cancer	0.000246	0.00263	CbGeAlD
Nilotinib—EPHB3—brain—brain cancer	0.000245	0.00263	CbGeAlD
Nilotinib—MAP2K5—medulla oblongata—brain cancer	0.000244	0.00261	CbGeAlD
Nilotinib—EPHA2—head—brain cancer	0.000242	0.0026	CbGeAlD
Nilotinib—PDGFRA—spinal cord—brain cancer	0.000241	0.00258	CbGeAlD
Nilotinib—TEK—endocrine gland—brain cancer	0.00024	0.00257	CbGeAlD
Nilotinib—ABL1—telencephalon—brain cancer	0.00024	0.00257	CbGeAlD
Nilotinib—CA9—cerebellum—brain cancer	0.000239	0.00256	CbGeAlD
Nilotinib—CSF1R—medulla oblongata—brain cancer	0.000238	0.00255	CbGeAlD
Nilotinib—MAPK14—central nervous system—brain cancer	0.000238	0.00255	CbGeAlD
Nilotinib—FGR—central nervous system—brain cancer	0.000237	0.00254	CbGeAlD
Nilotinib—TEK—head—brain cancer	0.000237	0.00253	CbGeAlD
Nilotinib—MAPK14—cerebellum—brain cancer	0.000233	0.00249	CbGeAlD
Nilotinib—KIT—gonad—brain cancer	0.00023	0.00246	CbGeAlD
Nilotinib—CA14—cerebellum—brain cancer	0.000226	0.00242	CbGeAlD
Nilotinib—EPHB6—head—brain cancer	0.000226	0.00242	CbGeAlD
Nilotinib—HCK—brain—brain cancer	0.000225	0.00242	CbGeAlD
Nilotinib—PDGFRB—gonad—brain cancer	0.000224	0.0024	CbGeAlD
Nilotinib—ABL2—brain—brain cancer	0.000224	0.0024	CbGeAlD
Nilotinib—KIT—pituitary gland—brain cancer	0.000224	0.0024	CbGeAlD
Nilotinib—MAP2K5—midbrain—brain cancer	0.000223	0.00239	CbGeAlD
Nilotinib—CA4—brainstem—brain cancer	0.000222	0.00237	CbGeAlD
Nilotinib—EPHA2—central nervous system—brain cancer	0.000221	0.00237	CbGeAlD
Nilotinib—CA7—brain—brain cancer	0.000221	0.00236	CbGeAlD
Nilotinib—EPHB4—cerebellum—brain cancer	0.000221	0.00236	CbGeAlD
Nilotinib—PDGFRB—pituitary gland—brain cancer	0.000219	0.00234	CbGeAlD
Nilotinib—CSF1R—midbrain—brain cancer	0.000218	0.00233	CbGeAlD
Nilotinib—MAP2K5—spinal cord—brain cancer	0.000218	0.00233	CbGeAlD
Nilotinib—PDGFRA—endocrine gland—brain cancer	0.000217	0.00233	CbGeAlD
Nilotinib—KIT—medulla oblongata—brain cancer	0.000216	0.00232	CbGeAlD
Nilotinib—TEK—central nervous system—brain cancer	0.000216	0.00231	CbGeAlD
Nilotinib—PDGFRA—head—brain cancer	0.000214	0.0023	CbGeAlD
Nilotinib—CSF1R—spinal cord—brain cancer	0.000212	0.00227	CbGeAlD
Nilotinib—PDGFRB—medulla oblongata—brain cancer	0.000211	0.00226	CbGeAlD
Nilotinib—TEK—cerebellum—brain cancer	0.000211	0.00226	CbGeAlD
Nilotinib—UGT1A1—endocrine gland—brain cancer	0.000207	0.00222	CbGeAlD
Nilotinib—EPHB6—central nervous system—brain cancer	0.000206	0.00221	CbGeAlD
Nilotinib—EPHA4—brain—brain cancer	0.000205	0.0022	CbGeAlD
Nilotinib—CYP2D6—hindbrain—brain cancer	0.000204	0.00218	CbGeAlD
Nilotinib—CA3—brain—brain cancer	0.000202	0.00217	CbGeAlD
Nilotinib—EPHB6—cerebellum—brain cancer	0.000202	0.00216	CbGeAlD
Nilotinib—CA12—endocrine gland—brain cancer	0.0002	0.00215	CbGeAlD
Nilotinib—ABL1—gonad—brain cancer	0.0002	0.00214	CbGeAlD
Nilotinib—CA12—head—brain cancer	0.000198	0.00212	CbGeAlD
Nilotinib—KIT—midbrain—brain cancer	0.000198	0.00212	CbGeAlD
Nilotinib—CA4—telencephalon—brain cancer	0.000197	0.00211	CbGeAlD
Nilotinib—MAP2K5—endocrine gland—brain cancer	0.000196	0.0021	CbGeAlD
Nilotinib—PDGFRA—central nervous system—brain cancer	0.000196	0.0021	CbGeAlD
Nilotinib—ABL1—pituitary gland—brain cancer	0.000195	0.00209	CbGeAlD
Nilotinib—MAP2K5—head—brain cancer	0.000193	0.00207	CbGeAlD
Nilotinib—PDGFRB—midbrain—brain cancer	0.000193	0.00207	CbGeAlD
Nilotinib—KIT—spinal cord—brain cancer	0.000193	0.00207	CbGeAlD
Nilotinib—PDGFRA—cerebellum—brain cancer	0.000191	0.00205	CbGeAlD
Nilotinib—CSF1R—endocrine gland—brain cancer	0.000191	0.00205	CbGeAlD
Nilotinib—MAPK14—brain—brain cancer	0.000189	0.00202	CbGeAlD
Nilotinib—CSF1R—head—brain cancer	0.000189	0.00202	CbGeAlD
Nilotinib—PDGFRB—spinal cord—brain cancer	0.000188	0.00202	CbGeAlD
Nilotinib—ABL1—medulla oblongata—brain cancer	0.000188	0.00202	CbGeAlD
Nilotinib—FGR—brain—brain cancer	0.000188	0.00202	CbGeAlD
Nilotinib—CA14—brain—brain cancer	0.000184	0.00197	CbGeAlD
Nilotinib—CA2—brainstem—brain cancer	0.000184	0.00197	CbGeAlD
Nilotinib—CA12—central nervous system—brain cancer	0.000181	0.00193	CbGeAlD
Nilotinib—EPHB4—brain—brain cancer	0.000179	0.00192	CbGeAlD
Nilotinib—Hypotension—Procarbazine—brain cancer	0.000179	0.00147	CcSEcCtD
Nilotinib—Neuropathy peripheral—Temozolomide—brain cancer	0.000178	0.00146	CcSEcCtD
Nilotinib—Stomatitis—Temozolomide—brain cancer	0.000177	0.00145	CcSEcCtD
Nilotinib—Urinary tract infection—Temozolomide—brain cancer	0.000177	0.00145	CcSEcCtD
Nilotinib—MAP2K5—central nervous system—brain cancer	0.000176	0.00189	CbGeAlD
Nilotinib—CA1—spinal cord—brain cancer	0.000176	0.00189	CbGeAlD
Nilotinib—EPHA2—brain—brain cancer	0.000176	0.00188	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000175	0.00143	CcSEcCtD
Nilotinib—KIT—endocrine gland—brain cancer	0.000174	0.00186	CbGeAlD
Nilotinib—Insomnia—Procarbazine—brain cancer	0.000173	0.00142	CcSEcCtD
Nilotinib—MAP2K5—cerebellum—brain cancer	0.000172	0.00185	CbGeAlD
Nilotinib—CSF1R—central nervous system—brain cancer	0.000172	0.00184	CbGeAlD
Nilotinib—Paraesthesia—Procarbazine—brain cancer	0.000172	0.00141	CcSEcCtD
Nilotinib—ABL1—midbrain—brain cancer	0.000172	0.00184	CbGeAlD
Nilotinib—Hepatobiliary disease—Temozolomide—brain cancer	0.000172	0.00141	CcSEcCtD
Nilotinib—TEK—brain—brain cancer	0.000171	0.00184	CbGeAlD
Nilotinib—KIT—head—brain cancer	0.000171	0.00184	CbGeAlD
Nilotinib—Haemoglobin—Carmustine—brain cancer	0.00017	0.00139	CcSEcCtD
Nilotinib—PDGFRB—endocrine gland—brain cancer	0.000169	0.00182	CbGeAlD
Nilotinib—Haemorrhage—Carmustine—brain cancer	0.000169	0.00138	CcSEcCtD
Nilotinib—Ill-defined disorder—Hydroxyurea—brain cancer	0.000169	0.00138	CcSEcCtD
Nilotinib—CSF1R—cerebellum—brain cancer	0.000168	0.0018	CbGeAlD
Nilotinib—Anaemia—Hydroxyurea—brain cancer	0.000168	0.00138	CcSEcCtD
Nilotinib—Hypoaesthesia—Carmustine—brain cancer	0.000168	0.00138	CcSEcCtD
Nilotinib—ABL1—spinal cord—brain cancer	0.000168	0.0018	CbGeAlD
Nilotinib—PDGFRB—head—brain cancer	0.000167	0.00179	CbGeAlD
Nilotinib—Decreased appetite—Procarbazine—brain cancer	0.000167	0.00137	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000166	0.00136	CcSEcCtD
Nilotinib—Oedema peripheral—Carmustine—brain cancer	0.000166	0.00136	CcSEcCtD
Nilotinib—Connective tissue disorder—Carmustine—brain cancer	0.000166	0.00136	CcSEcCtD
Nilotinib—Fatigue—Procarbazine—brain cancer	0.000165	0.00135	CcSEcCtD
Nilotinib—Haemoglobin—Temozolomide—brain cancer	0.000164	0.00134	CcSEcCtD
Nilotinib—Malaise—Hydroxyurea—brain cancer	0.000164	0.00134	CcSEcCtD
Nilotinib—Constipation—Procarbazine—brain cancer	0.000164	0.00134	CcSEcCtD
Nilotinib—Pain—Procarbazine—brain cancer	0.000164	0.00134	CcSEcCtD
Nilotinib—EPHB6—brain—brain cancer	0.000164	0.00175	CbGeAlD
Nilotinib—Hepatitis—Temozolomide—brain cancer	0.000163	0.00134	CcSEcCtD
Nilotinib—Haemorrhage—Temozolomide—brain cancer	0.000163	0.00134	CcSEcCtD
Nilotinib—CA2—telencephalon—brain cancer	0.000163	0.00175	CbGeAlD
Nilotinib—Leukopenia—Hydroxyurea—brain cancer	0.000163	0.00133	CcSEcCtD
Nilotinib—Visual impairment—Carmustine—brain cancer	0.000163	0.00133	CcSEcCtD
Nilotinib—Hypoaesthesia—Temozolomide—brain cancer	0.000162	0.00133	CcSEcCtD
Nilotinib—Pharyngitis—Temozolomide—brain cancer	0.000162	0.00133	CcSEcCtD
Nilotinib—Urinary tract disorder—Temozolomide—brain cancer	0.000161	0.00132	CcSEcCtD
Nilotinib—Oedema peripheral—Temozolomide—brain cancer	0.000161	0.00132	CcSEcCtD
Nilotinib—Connective tissue disorder—Temozolomide—brain cancer	0.00016	0.00131	CcSEcCtD
Nilotinib—CA4—pituitary gland—brain cancer	0.00016	0.00172	CbGeAlD
Nilotinib—Urethral disorder—Temozolomide—brain cancer	0.00016	0.00131	CcSEcCtD
Nilotinib—CA1—endocrine gland—brain cancer	0.000159	0.0017	CbGeAlD
Nilotinib—Feeling abnormal—Procarbazine—brain cancer	0.000158	0.00129	CcSEcCtD
Nilotinib—Eye disorder—Carmustine—brain cancer	0.000158	0.00129	CcSEcCtD
Nilotinib—Visual impairment—Temozolomide—brain cancer	0.000157	0.00129	CcSEcCtD
Nilotinib—Gastrointestinal pain—Procarbazine—brain cancer	0.000157	0.00128	CcSEcCtD
Nilotinib—CA1—head—brain cancer	0.000157	0.00168	CbGeAlD
Nilotinib—Flushing—Carmustine—brain cancer	0.000157	0.00128	CcSEcCtD
Nilotinib—KIT—central nervous system—brain cancer	0.000156	0.00168	CbGeAlD
Nilotinib—PDGFRA—brain—brain cancer	0.000155	0.00166	CbGeAlD
Nilotinib—Pancytopenia—Etoposide—brain cancer	0.000155	0.00127	CcSEcCtD
Nilotinib—CA4—medulla oblongata—brain cancer	0.000155	0.00166	CbGeAlD
Nilotinib—Erythema multiforme—Temozolomide—brain cancer	0.000154	0.00126	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000154	0.00126	CcSEcCtD
Nilotinib—ABCB1—blood vessel—brain cancer	0.000154	0.00164	CbGeAlD
Nilotinib—Discomfort—Hydroxyurea—brain cancer	0.000153	0.00125	CcSEcCtD
Nilotinib—KIT—cerebellum—brain cancer	0.000153	0.00164	CbGeAlD
Nilotinib—PDGFRB—central nervous system—brain cancer	0.000153	0.00164	CbGeAlD
Nilotinib—Neutropenia—Etoposide—brain cancer	0.000152	0.00125	CcSEcCtD
Nilotinib—Eye disorder—Temozolomide—brain cancer	0.000152	0.00125	CcSEcCtD
Nilotinib—Urticaria—Procarbazine—brain cancer	0.000152	0.00125	CcSEcCtD
Nilotinib—Tinnitus—Temozolomide—brain cancer	0.000152	0.00125	CcSEcCtD
Nilotinib—Abdominal pain—Procarbazine—brain cancer	0.000152	0.00124	CcSEcCtD
Nilotinib—Body temperature increased—Procarbazine—brain cancer	0.000152	0.00124	CcSEcCtD
Nilotinib—Cardiac disorder—Temozolomide—brain cancer	0.000151	0.00124	CcSEcCtD
Nilotinib—Flushing—Temozolomide—brain cancer	0.000151	0.00124	CcSEcCtD
Nilotinib—ABL1—endocrine gland—brain cancer	0.000151	0.00162	CbGeAlD
Nilotinib—ABCG2—telencephalon—brain cancer	0.000151	0.00162	CbGeAlD
Nilotinib—Arrhythmia—Carmustine—brain cancer	0.000151	0.00124	CcSEcCtD
Nilotinib—PDGFRB—cerebellum—brain cancer	0.000149	0.0016	CbGeAlD
Nilotinib—Alopecia—Carmustine—brain cancer	0.000149	0.00122	CcSEcCtD
Nilotinib—ABL1—head—brain cancer	0.000149	0.0016	CbGeAlD
Nilotinib—Oedema—Hydroxyurea—brain cancer	0.000148	0.00122	CcSEcCtD
Nilotinib—Angiopathy—Temozolomide—brain cancer	0.000148	0.00121	CcSEcCtD
Nilotinib—Mental disorder—Carmustine—brain cancer	0.000148	0.00121	CcSEcCtD
Nilotinib—Infection—Hydroxyurea—brain cancer	0.000147	0.00121	CcSEcCtD
Nilotinib—Immune system disorder—Temozolomide—brain cancer	0.000147	0.00121	CcSEcCtD
Nilotinib—Mediastinal disorder—Temozolomide—brain cancer	0.000147	0.0012	CcSEcCtD
Nilotinib—Erythema—Carmustine—brain cancer	0.000147	0.0012	CcSEcCtD
Nilotinib—Malnutrition—Carmustine—brain cancer	0.000147	0.0012	CcSEcCtD
Nilotinib—Chills—Temozolomide—brain cancer	0.000146	0.0012	CcSEcCtD
Nilotinib—Pneumonia—Etoposide—brain cancer	0.000146	0.0012	CcSEcCtD
Nilotinib—Nervous system disorder—Hydroxyurea—brain cancer	0.000145	0.00119	CcSEcCtD
Nilotinib—Infestation NOS—Etoposide—brain cancer	0.000145	0.00119	CcSEcCtD
Nilotinib—Infestation—Etoposide—brain cancer	0.000145	0.00119	CcSEcCtD
Nilotinib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000145	0.00119	CcSEcCtD
Nilotinib—Alopecia—Temozolomide—brain cancer	0.000144	0.00118	CcSEcCtD
Nilotinib—Skin disorder—Hydroxyurea—brain cancer	0.000144	0.00118	CcSEcCtD
Nilotinib—CA12—brain—brain cancer	0.000143	0.00154	CbGeAlD
Nilotinib—Acute coronary syndrome—Etoposide—brain cancer	0.000143	0.00117	CcSEcCtD
Nilotinib—CA1—central nervous system—brain cancer	0.000143	0.00153	CbGeAlD
Nilotinib—Renal failure—Etoposide—brain cancer	0.000143	0.00117	CcSEcCtD
Nilotinib—Mental disorder—Temozolomide—brain cancer	0.000143	0.00117	CcSEcCtD
Nilotinib—Neuropathy peripheral—Etoposide—brain cancer	0.000143	0.00117	CcSEcCtD
Nilotinib—Myocardial infarction—Etoposide—brain cancer	0.000143	0.00117	CcSEcCtD
Nilotinib—Back pain—Carmustine—brain cancer	0.000142	0.00116	CcSEcCtD
Nilotinib—Erythema—Temozolomide—brain cancer	0.000142	0.00116	CcSEcCtD
Nilotinib—Malnutrition—Temozolomide—brain cancer	0.000142	0.00116	CcSEcCtD
Nilotinib—Stomatitis—Etoposide—brain cancer	0.000142	0.00116	CcSEcCtD
Nilotinib—Jaundice—Etoposide—brain cancer	0.000142	0.00116	CcSEcCtD
Nilotinib—Anorexia—Hydroxyurea—brain cancer	0.000141	0.00116	CcSEcCtD
Nilotinib—CA4—midbrain—brain cancer	0.000141	0.00151	CbGeAlD
Nilotinib—Hypersensitivity—Procarbazine—brain cancer	0.000141	0.00116	CcSEcCtD
Nilotinib—MAP2K5—brain—brain cancer	0.00014	0.0015	CbGeAlD
Nilotinib—Dysgeusia—Temozolomide—brain cancer	0.000139	0.00114	CcSEcCtD
Nilotinib—Vision blurred—Carmustine—brain cancer	0.000138	0.00113	CcSEcCtD
Nilotinib—CA4—spinal cord—brain cancer	0.000138	0.00148	CbGeAlD
Nilotinib—Tremor—Carmustine—brain cancer	0.000138	0.00113	CcSEcCtD
Nilotinib—Asthenia—Procarbazine—brain cancer	0.000138	0.00113	CcSEcCtD
Nilotinib—Hepatobiliary disease—Etoposide—brain cancer	0.000137	0.00113	CcSEcCtD
Nilotinib—Back pain—Temozolomide—brain cancer	0.000137	0.00113	CcSEcCtD
Nilotinib—CSF1R—brain—brain cancer	0.000137	0.00146	CbGeAlD
Nilotinib—ABL1—central nervous system—brain cancer	0.000136	0.00146	CbGeAlD
Nilotinib—Anaemia—Carmustine—brain cancer	0.000136	0.00111	CcSEcCtD
Nilotinib—Pruritus—Procarbazine—brain cancer	0.000136	0.00111	CcSEcCtD
Nilotinib—Vision blurred—Temozolomide—brain cancer	0.000134	0.0011	CcSEcCtD
Nilotinib—ABL1—cerebellum—brain cancer	0.000133	0.00143	CbGeAlD
Nilotinib—Tremor—Temozolomide—brain cancer	0.000133	0.00109	CcSEcCtD
Nilotinib—CA2—pituitary gland—brain cancer	0.000133	0.00142	CbGeAlD
Nilotinib—Dyspnoea—Hydroxyurea—brain cancer	0.000132	0.00108	CcSEcCtD
Nilotinib—Ill-defined disorder—Temozolomide—brain cancer	0.000132	0.00108	CcSEcCtD
Nilotinib—Leukopenia—Carmustine—brain cancer	0.000132	0.00108	CcSEcCtD
Nilotinib—Anaemia—Temozolomide—brain cancer	0.000131	0.00108	CcSEcCtD
Nilotinib—Diarrhoea—Procarbazine—brain cancer	0.000131	0.00107	CcSEcCtD
Nilotinib—Dyspepsia—Hydroxyurea—brain cancer	0.000131	0.00107	CcSEcCtD
Nilotinib—Hypoaesthesia—Etoposide—brain cancer	0.00013	0.00106	CcSEcCtD
Nilotinib—Decreased appetite—Hydroxyurea—brain cancer	0.000129	0.00106	CcSEcCtD
Nilotinib—Urinary tract disorder—Etoposide—brain cancer	0.000129	0.00106	CcSEcCtD
Nilotinib—CA2—medulla oblongata—brain cancer	0.000128	0.00137	CbGeAlD
Nilotinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000128	0.00105	CcSEcCtD
Nilotinib—Malaise—Temozolomide—brain cancer	0.000128	0.00105	CcSEcCtD
Nilotinib—Urethral disorder—Etoposide—brain cancer	0.000128	0.00105	CcSEcCtD
Nilotinib—Fatigue—Hydroxyurea—brain cancer	0.000128	0.00105	CcSEcCtD
Nilotinib—Vertigo—Temozolomide—brain cancer	0.000128	0.00105	CcSEcCtD
Nilotinib—Leukopenia—Temozolomide—brain cancer	0.000127	0.00104	CcSEcCtD
Nilotinib—Hypertension—Carmustine—brain cancer	0.000127	0.00104	CcSEcCtD
Nilotinib—Constipation—Hydroxyurea—brain cancer	0.000127	0.00104	CcSEcCtD
Nilotinib—Pain—Hydroxyurea—brain cancer	0.000127	0.00104	CcSEcCtD
Nilotinib—Dizziness—Procarbazine—brain cancer	0.000127	0.00104	CcSEcCtD
Nilotinib—CYP2C8—pituitary gland—brain cancer	0.000126	0.00135	CbGeAlD
Nilotinib—Palpitations—Temozolomide—brain cancer	0.000125	0.00103	CcSEcCtD
Nilotinib—Myalgia—Carmustine—brain cancer	0.000125	0.00103	CcSEcCtD
Nilotinib—Chest pain—Carmustine—brain cancer	0.000125	0.00103	CcSEcCtD
Nilotinib—Anxiety—Carmustine—brain cancer	0.000125	0.00102	CcSEcCtD
Nilotinib—KIT—brain—brain cancer	0.000124	0.00133	CbGeAlD
Nilotinib—CA4—endocrine gland—brain cancer	0.000124	0.00133	CbGeAlD
Nilotinib—Cough—Temozolomide—brain cancer	0.000124	0.00102	CcSEcCtD
Nilotinib—Erythema multiforme—Etoposide—brain cancer	0.000123	0.00101	CcSEcCtD
Nilotinib—ABCG2—pituitary gland—brain cancer	0.000123	0.00132	CbGeAlD
Nilotinib—Hypertension—Temozolomide—brain cancer	0.000123	0.001	CcSEcCtD
Nilotinib—CA4—head—brain cancer	0.000122	0.00131	CbGeAlD
Nilotinib—Feeling abnormal—Hydroxyurea—brain cancer	0.000122	0.001	CcSEcCtD
Nilotinib—Eye disorder—Etoposide—brain cancer	0.000122	0.001	CcSEcCtD
Nilotinib—Vomiting—Procarbazine—brain cancer	0.000122	0.000999	CcSEcCtD
Nilotinib—PDGFRB—brain—brain cancer	0.000121	0.0013	CbGeAlD
Nilotinib—Cardiac disorder—Etoposide—brain cancer	0.000121	0.000993	CcSEcCtD
Nilotinib—Flushing—Etoposide—brain cancer	0.000121	0.000993	CcSEcCtD
Nilotinib—Confusional state—Carmustine—brain cancer	0.000121	0.000991	CcSEcCtD
Nilotinib—Arthralgia—Temozolomide—brain cancer	0.000121	0.000991	CcSEcCtD
Nilotinib—Myalgia—Temozolomide—brain cancer	0.000121	0.000991	CcSEcCtD
Nilotinib—Rash—Procarbazine—brain cancer	0.000121	0.000991	CcSEcCtD
Nilotinib—Dermatitis—Procarbazine—brain cancer	0.000121	0.00099	CcSEcCtD
Nilotinib—Anxiety—Temozolomide—brain cancer	0.00012	0.000987	CcSEcCtD
Nilotinib—Headache—Procarbazine—brain cancer	0.00012	0.000984	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.00012	0.000984	CcSEcCtD
Nilotinib—Oedema—Carmustine—brain cancer	0.00012	0.000983	CcSEcCtD
Nilotinib—Discomfort—Temozolomide—brain cancer	0.000119	0.000979	CcSEcCtD
Nilotinib—Infection—Carmustine—brain cancer	0.000119	0.000976	CcSEcCtD
Nilotinib—ABCG2—medulla oblongata—brain cancer	0.000119	0.00127	CbGeAlD
Nilotinib—Angiopathy—Etoposide—brain cancer	0.000118	0.000971	CcSEcCtD
Nilotinib—Dry mouth—Temozolomide—brain cancer	0.000118	0.000969	CcSEcCtD
Nilotinib—Immune system disorder—Etoposide—brain cancer	0.000118	0.000966	CcSEcCtD
Nilotinib—Mediastinal disorder—Etoposide—brain cancer	0.000118	0.000964	CcSEcCtD
Nilotinib—Thrombocytopenia—Carmustine—brain cancer	0.000117	0.000962	CcSEcCtD
Nilotinib—Body temperature increased—Hydroxyurea—brain cancer	0.000117	0.000961	CcSEcCtD
Nilotinib—CA2—midbrain—brain cancer	0.000117	0.00125	CbGeAlD
Nilotinib—Chills—Etoposide—brain cancer	0.000117	0.00096	CcSEcCtD
Nilotinib—Tachycardia—Carmustine—brain cancer	0.000117	0.000959	CcSEcCtD
Nilotinib—Confusional state—Temozolomide—brain cancer	0.000117	0.000958	CcSEcCtD
Nilotinib—CYP2D6—brainstem—brain cancer	0.000117	0.00125	CbGeAlD
Nilotinib—CYP2B6—gonad—brain cancer	0.000116	0.00125	CbGeAlD
Nilotinib—Oedema—Temozolomide—brain cancer	0.000116	0.00095	CcSEcCtD
Nilotinib—Alopecia—Etoposide—brain cancer	0.000115	0.000945	CcSEcCtD
Nilotinib—Infection—Temozolomide—brain cancer	0.000115	0.000944	CcSEcCtD
Nilotinib—Anorexia—Carmustine—brain cancer	0.000114	0.000937	CcSEcCtD
Nilotinib—CA2—spinal cord—brain cancer	0.000114	0.00122	CbGeAlD
Nilotinib—Nausea—Procarbazine—brain cancer	0.000114	0.000933	CcSEcCtD
Nilotinib—Nervous system disorder—Temozolomide—brain cancer	0.000114	0.000931	CcSEcCtD
Nilotinib—CA1—brain—brain cancer	0.000114	0.00122	CbGeAlD
Nilotinib—Thrombocytopenia—Temozolomide—brain cancer	0.000113	0.00093	CcSEcCtD
Nilotinib—Skin disorder—Temozolomide—brain cancer	0.000113	0.000923	CcSEcCtD
Nilotinib—Hypotension—Carmustine—brain cancer	0.000112	0.000918	CcSEcCtD
Nilotinib—Hyperhidrosis—Temozolomide—brain cancer	0.000112	0.000918	CcSEcCtD
Nilotinib—CA4—central nervous system—brain cancer	0.000112	0.0012	CbGeAlD
Nilotinib—Dysgeusia—Etoposide—brain cancer	0.000111	0.000912	CcSEcCtD
Nilotinib—Anorexia—Temozolomide—brain cancer	0.00011	0.000905	CcSEcCtD
Nilotinib—Back pain—Etoposide—brain cancer	0.00011	0.000901	CcSEcCtD
Nilotinib—Hypersensitivity—Hydroxyurea—brain cancer	0.000109	0.000896	CcSEcCtD
Nilotinib—CA4—cerebellum—brain cancer	0.000109	0.00117	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000109	0.000895	CcSEcCtD
Nilotinib—Muscle spasms—Etoposide—brain cancer	0.000109	0.000895	CcSEcCtD
Nilotinib—ABCG2—midbrain—brain cancer	0.000108	0.00116	CbGeAlD
Nilotinib—Insomnia—Carmustine—brain cancer	0.000108	0.000889	CcSEcCtD
Nilotinib—ABL1—brain—brain cancer	0.000108	0.00116	CbGeAlD
Nilotinib—Paraesthesia—Carmustine—brain cancer	0.000108	0.000883	CcSEcCtD
Nilotinib—Dyspnoea—Carmustine—brain cancer	0.000107	0.000876	CcSEcCtD
Nilotinib—Asthenia—Hydroxyurea—brain cancer	0.000106	0.000872	CcSEcCtD
Nilotinib—ABCG2—spinal cord—brain cancer	0.000106	0.00113	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000106	0.000865	CcSEcCtD
Nilotinib—Ill-defined disorder—Etoposide—brain cancer	0.000105	0.000864	CcSEcCtD
Nilotinib—Anaemia—Etoposide—brain cancer	0.000105	0.000861	CcSEcCtD
Nilotinib—Insomnia—Temozolomide—brain cancer	0.000105	0.000859	CcSEcCtD
Nilotinib—Decreased appetite—Carmustine—brain cancer	0.000104	0.000854	CcSEcCtD
Nilotinib—Paraesthesia—Temozolomide—brain cancer	0.000104	0.000853	CcSEcCtD
Nilotinib—CYP2D6—telencephalon—brain cancer	0.000104	0.00111	CbGeAlD
Nilotinib—Gastrointestinal disorder—Carmustine—brain cancer	0.000104	0.000849	CcSEcCtD
Nilotinib—Dyspnoea—Temozolomide—brain cancer	0.000103	0.000847	CcSEcCtD
Nilotinib—CA2—endocrine gland—brain cancer	0.000103	0.0011	CbGeAlD
Nilotinib—Pain—Carmustine—brain cancer	0.000103	0.000841	CcSEcCtD
Nilotinib—Constipation—Carmustine—brain cancer	0.000103	0.000841	CcSEcCtD
Nilotinib—Malaise—Etoposide—brain cancer	0.000102	0.00084	CcSEcCtD
Nilotinib—Vertigo—Etoposide—brain cancer	0.000102	0.000837	CcSEcCtD
Nilotinib—Dyspepsia—Temozolomide—brain cancer	0.000102	0.000836	CcSEcCtD
Nilotinib—Leukopenia—Etoposide—brain cancer	0.000102	0.000834	CcSEcCtD
Nilotinib—CA2—head—brain cancer	0.000102	0.00109	CbGeAlD
Nilotinib—Diarrhoea—Hydroxyurea—brain cancer	0.000101	0.000832	CcSEcCtD
Nilotinib—Decreased appetite—Temozolomide—brain cancer	0.000101	0.000826	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Temozolomide—brain cancer	0.0001	0.00082	CcSEcCtD
Nilotinib—Fatigue—Temozolomide—brain cancer	9.99e-05	0.000819	CcSEcCtD
Nilotinib—Loss of consciousness—Etoposide—brain cancer	9.99e-05	0.000819	CcSEcCtD
Nilotinib—Cough—Etoposide—brain cancer	9.91e-05	0.000813	CcSEcCtD
Nilotinib—Pain—Temozolomide—brain cancer	9.91e-05	0.000812	CcSEcCtD
Nilotinib—Constipation—Temozolomide—brain cancer	9.91e-05	0.000812	CcSEcCtD
Nilotinib—Feeling abnormal—Carmustine—brain cancer	9.88e-05	0.00081	CcSEcCtD
Nilotinib—Hypertension—Etoposide—brain cancer	9.81e-05	0.000804	CcSEcCtD
Nilotinib—Dizziness—Hydroxyurea—brain cancer	9.81e-05	0.000804	CcSEcCtD
Nilotinib—Gastrointestinal pain—Carmustine—brain cancer	9.81e-05	0.000804	CcSEcCtD
Nilotinib—CYP2C8—endocrine gland—brain cancer	9.8e-05	0.00105	CbGeAlD
Nilotinib—Chest pain—Etoposide—brain cancer	9.67e-05	0.000793	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	9.61e-05	0.000787	CcSEcCtD
Nilotinib—Discomfort—Etoposide—brain cancer	9.56e-05	0.000783	CcSEcCtD
Nilotinib—Feeling abnormal—Temozolomide—brain cancer	9.55e-05	0.000783	CcSEcCtD
Nilotinib—Abdominal pain—Carmustine—brain cancer	9.48e-05	0.000777	CcSEcCtD
Nilotinib—Body temperature increased—Carmustine—brain cancer	9.48e-05	0.000777	CcSEcCtD
Nilotinib—Gastrointestinal pain—Temozolomide—brain cancer	9.48e-05	0.000777	CcSEcCtD
Nilotinib—Vomiting—Hydroxyurea—brain cancer	9.43e-05	0.000773	CcSEcCtD
Nilotinib—Rash—Hydroxyurea—brain cancer	9.35e-05	0.000767	CcSEcCtD
Nilotinib—Confusional state—Etoposide—brain cancer	9.35e-05	0.000766	CcSEcCtD
Nilotinib—Dermatitis—Hydroxyurea—brain cancer	9.34e-05	0.000766	CcSEcCtD
Nilotinib—Headache—Hydroxyurea—brain cancer	9.29e-05	0.000762	CcSEcCtD
Nilotinib—CA2—central nervous system—brain cancer	9.27e-05	0.000993	CbGeAlD
Nilotinib—Infection—Etoposide—brain cancer	9.21e-05	0.000755	CcSEcCtD
Nilotinib—Urticaria—Temozolomide—brain cancer	9.21e-05	0.000755	CcSEcCtD
Nilotinib—Body temperature increased—Temozolomide—brain cancer	9.16e-05	0.000751	CcSEcCtD
Nilotinib—Abdominal pain—Temozolomide—brain cancer	9.16e-05	0.000751	CcSEcCtD
Nilotinib—Thrombocytopenia—Etoposide—brain cancer	9.08e-05	0.000744	CcSEcCtD
Nilotinib—CA2—cerebellum—brain cancer	9.06e-05	0.000971	CbGeAlD
Nilotinib—Tachycardia—Etoposide—brain cancer	9.05e-05	0.000742	CcSEcCtD
Nilotinib—Skin disorder—Etoposide—brain cancer	9.01e-05	0.000738	CcSEcCtD
Nilotinib—Hyperhidrosis—Etoposide—brain cancer	8.96e-05	0.000735	CcSEcCtD
Nilotinib—CA4—brain—brain cancer	8.88e-05	0.000951	CbGeAlD
Nilotinib—Anorexia—Etoposide—brain cancer	8.84e-05	0.000724	CcSEcCtD
Nilotinib—Hypersensitivity—Carmustine—brain cancer	8.83e-05	0.000724	CcSEcCtD
Nilotinib—Nausea—Hydroxyurea—brain cancer	8.81e-05	0.000722	CcSEcCtD
Nilotinib—CYP2B6—endocrine gland—brain cancer	8.79e-05	0.000942	CbGeAlD
Nilotinib—CYP2C9—endocrine gland—brain cancer	8.7e-05	0.000932	CbGeAlD
Nilotinib—CYP2B6—head—brain cancer	8.68e-05	0.00093	CbGeAlD
Nilotinib—Hypotension—Etoposide—brain cancer	8.66e-05	0.00071	CcSEcCtD
Nilotinib—Asthenia—Carmustine—brain cancer	8.6e-05	0.000705	CcSEcCtD
Nilotinib—Hypersensitivity—Temozolomide—brain cancer	8.54e-05	0.0007	CcSEcCtD
Nilotinib—ABCG2—cerebellum—brain cancer	8.39e-05	0.000899	CbGeAlD
Nilotinib—Paraesthesia—Etoposide—brain cancer	8.33e-05	0.000682	CcSEcCtD
Nilotinib—Asthenia—Temozolomide—brain cancer	8.31e-05	0.000681	CcSEcCtD
Nilotinib—Dyspnoea—Etoposide—brain cancer	8.27e-05	0.000678	CcSEcCtD
Nilotinib—Diarrhoea—Carmustine—brain cancer	8.2e-05	0.000672	CcSEcCtD
Nilotinib—Pruritus—Temozolomide—brain cancer	8.2e-05	0.000672	CcSEcCtD
Nilotinib—Decreased appetite—Etoposide—brain cancer	8.06e-05	0.000661	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Etoposide—brain cancer	8.01e-05	0.000656	CcSEcCtD
Nilotinib—Fatigue—Etoposide—brain cancer	7.99e-05	0.000655	CcSEcCtD
Nilotinib—Dizziness—Carmustine—brain cancer	7.93e-05	0.00065	CcSEcCtD
Nilotinib—Pain—Etoposide—brain cancer	7.93e-05	0.00065	CcSEcCtD
Nilotinib—Constipation—Etoposide—brain cancer	7.93e-05	0.00065	CcSEcCtD
Nilotinib—Diarrhoea—Temozolomide—brain cancer	7.93e-05	0.00065	CcSEcCtD
Nilotinib—CYP2B6—central nervous system—brain cancer	7.92e-05	0.000848	CbGeAlD
Nilotinib—Dizziness—Temozolomide—brain cancer	7.66e-05	0.000628	CcSEcCtD
Nilotinib—Feeling abnormal—Etoposide—brain cancer	7.64e-05	0.000626	CcSEcCtD
Nilotinib—Vomiting—Carmustine—brain cancer	7.62e-05	0.000625	CcSEcCtD
Nilotinib—Gastrointestinal pain—Etoposide—brain cancer	7.58e-05	0.000622	CcSEcCtD
Nilotinib—Rash—Carmustine—brain cancer	7.56e-05	0.00062	CcSEcCtD
Nilotinib—Dermatitis—Carmustine—brain cancer	7.55e-05	0.000619	CcSEcCtD
Nilotinib—Headache—Carmustine—brain cancer	7.51e-05	0.000616	CcSEcCtD
Nilotinib—ABCB1—telencephalon—brain cancer	7.45e-05	0.000798	CbGeAlD
Nilotinib—Vomiting—Temozolomide—brain cancer	7.37e-05	0.000604	CcSEcCtD
Nilotinib—Urticaria—Etoposide—brain cancer	7.37e-05	0.000604	CcSEcCtD
Nilotinib—CA2—brain—brain cancer	7.36e-05	0.000788	CbGeAlD
Nilotinib—Body temperature increased—Etoposide—brain cancer	7.33e-05	0.000601	CcSEcCtD
Nilotinib—Abdominal pain—Etoposide—brain cancer	7.33e-05	0.000601	CcSEcCtD
Nilotinib—Rash—Temozolomide—brain cancer	7.31e-05	0.000599	CcSEcCtD
Nilotinib—Dermatitis—Temozolomide—brain cancer	7.3e-05	0.000598	CcSEcCtD
Nilotinib—Headache—Temozolomide—brain cancer	7.26e-05	0.000595	CcSEcCtD
Nilotinib—Nausea—Carmustine—brain cancer	7.12e-05	0.000584	CcSEcCtD
Nilotinib—CYP2C8—brain—brain cancer	7.01e-05	0.000751	CbGeAlD
Nilotinib—Nausea—Temozolomide—brain cancer	6.88e-05	0.000564	CcSEcCtD
Nilotinib—Hypersensitivity—Etoposide—brain cancer	6.83e-05	0.00056	CcSEcCtD
Nilotinib—ABCG2—brain—brain cancer	6.82e-05	0.00073	CbGeAlD
Nilotinib—Asthenia—Etoposide—brain cancer	6.65e-05	0.000545	CcSEcCtD
Nilotinib—CYP3A4—endocrine gland—brain cancer	6.64e-05	0.000711	CbGeAlD
Nilotinib—Pruritus—Etoposide—brain cancer	6.56e-05	0.000538	CcSEcCtD
Nilotinib—CYP2D6—endocrine gland—brain cancer	6.53e-05	0.0007	CbGeAlD
Nilotinib—CYP2D6—head—brain cancer	6.45e-05	0.000691	CbGeAlD
Nilotinib—Diarrhoea—Etoposide—brain cancer	6.34e-05	0.00052	CcSEcCtD
Nilotinib—CYP2B6—brain—brain cancer	6.29e-05	0.000674	CbGeAlD
Nilotinib—ABCB1—gonad—brain cancer	6.22e-05	0.000666	CbGeAlD
Nilotinib—Dizziness—Etoposide—brain cancer	6.13e-05	0.000503	CcSEcCtD
Nilotinib—ABCB1—pituitary gland—brain cancer	6.06e-05	0.00065	CbGeAlD
Nilotinib—CYP3A4—central nervous system—brain cancer	5.98e-05	0.000641	CbGeAlD
Nilotinib—Vomiting—Etoposide—brain cancer	5.9e-05	0.000483	CcSEcCtD
Nilotinib—CYP2D6—central nervous system—brain cancer	5.88e-05	0.00063	CbGeAlD
Nilotinib—ABCB1—medulla oblongata—brain cancer	5.85e-05	0.000627	CbGeAlD
Nilotinib—Rash—Etoposide—brain cancer	5.85e-05	0.000479	CcSEcCtD
Nilotinib—Dermatitis—Etoposide—brain cancer	5.84e-05	0.000479	CcSEcCtD
Nilotinib—Headache—Etoposide—brain cancer	5.81e-05	0.000476	CcSEcCtD
Nilotinib—CYP2D6—cerebellum—brain cancer	5.75e-05	0.000616	CbGeAlD
Nilotinib—Nausea—Etoposide—brain cancer	5.51e-05	0.000451	CcSEcCtD
Nilotinib—ABCB1—midbrain—brain cancer	5.35e-05	0.000573	CbGeAlD
Nilotinib—ABCB1—spinal cord—brain cancer	5.22e-05	0.000559	CbGeAlD
Nilotinib—ABCB1—endocrine gland—brain cancer	4.7e-05	0.000503	CbGeAlD
Nilotinib—CYP2D6—brain—brain cancer	4.67e-05	0.000501	CbGeAlD
Nilotinib—ABCB1—head—brain cancer	4.64e-05	0.000497	CbGeAlD
Nilotinib—ABCB1—central nervous system—brain cancer	4.23e-05	0.000454	CbGeAlD
Nilotinib—ABCB1—cerebellum—brain cancer	4.14e-05	0.000443	CbGeAlD
Nilotinib—ABCB1—brain—brain cancer	3.36e-05	0.00036	CbGeAlD
Nilotinib—LCK—Hemostasis—VEGFA—brain cancer	4.82e-06	3.62e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL2—brain cancer	4.82e-06	3.62e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—MYC—brain cancer	4.82e-06	3.62e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—ERBB2—brain cancer	4.8e-06	3.6e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IRS2—brain cancer	4.79e-06	3.59e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EGFR—brain cancer	4.77e-06	3.57e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EGFR—brain cancer	4.75e-06	3.56e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SPP1—brain cancer	4.74e-06	3.55e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—IDH1—brain cancer	4.72e-06	3.54e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—EGFR—brain cancer	4.72e-06	3.54e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—EGFR—brain cancer	4.68e-06	3.51e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CTNNB1—brain cancer	4.66e-06	3.49e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EGFR—brain cancer	4.63e-06	3.47e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—EGFR—brain cancer	4.63e-06	3.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HES1—brain cancer	4.62e-06	3.46e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—EGFR—brain cancer	4.61e-06	3.46e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—EGFR—brain cancer	4.58e-06	3.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—RELA—brain cancer	4.57e-06	3.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—ERBB2—brain cancer	4.54e-06	3.41e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IRS2—brain cancer	4.52e-06	3.39e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EGFR—brain cancer	4.52e-06	3.39e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HES1—brain cancer	4.52e-06	3.39e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOTCH2—brain cancer	4.52e-06	3.39e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—IDH1—brain cancer	4.45e-06	3.34e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—brain cancer	4.45e-06	3.33e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CG—brain cancer	4.43e-06	3.32e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—APC—brain cancer	4.43e-06	3.32e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—ERBB2—brain cancer	4.43e-06	3.32e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—brain cancer	4.43e-06	3.32e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IRS2—brain cancer	4.42e-06	3.31e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	4.41e-06	3.31e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—IDH1—brain cancer	4.41e-06	3.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PDGFRA—brain cancer	4.39e-06	3.29e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CG—brain cancer	4.39e-06	3.29e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—APC—brain cancer	4.39e-06	3.29e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL2—brain cancer	4.35e-06	3.26e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—RELA—brain cancer	4.35e-06	3.26e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ERBB2—brain cancer	4.32e-06	3.24e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VAV1—brain cancer	4.31e-06	3.23e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PDGFRA—brain cancer	4.3e-06	3.23e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ENO2—brain cancer	4.29e-06	3.21e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HES1—brain cancer	4.28e-06	3.21e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IRS2—brain cancer	4.28e-06	3.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SPP1—brain cancer	4.27e-06	3.2e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CTNNB1—brain cancer	4.26e-06	3.19e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—brain cancer	4.22e-06	3.16e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CTNNB1—brain cancer	4.2e-06	3.15e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—ERBB2—brain cancer	4.19e-06	3.14e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SPP1—brain cancer	4.18e-06	3.13e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	4.16e-06	3.12e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—RELA—brain cancer	4.13e-06	3.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—RELA—brain cancer	4.12e-06	3.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—brain cancer	4.12e-06	3.09e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ERBB2—brain cancer	4.11e-06	3.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—ERBB2—brain cancer	4.09e-06	3.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PDGFRA—brain cancer	4.08e-06	3.06e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—STAT3—brain cancer	4.06e-06	3.04e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—RELA—brain cancer	4.03e-06	3.02e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—RELA—brain cancer	4.01e-06	3.01e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—ERBB2—brain cancer	4.01e-06	3e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—APC—brain cancer	4e-06	3e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CG—brain cancer	4e-06	3e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—ERBB2—brain cancer	3.99e-06	2.99e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2C9—brain cancer	3.98e-06	2.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CTNNB1—brain cancer	3.97e-06	2.98e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SPP1—brain cancer	3.96e-06	2.97e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—brain cancer	3.91e-06	2.93e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—brain cancer	3.91e-06	2.93e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—APC—brain cancer	3.9e-06	2.93e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CTNNB1—brain cancer	3.88e-06	2.91e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IRS2—brain cancer	3.86e-06	2.89e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—RELA—brain cancer	3.82e-06	2.87e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCND1—brain cancer	3.82e-06	2.86e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ERBB2—brain cancer	3.8e-06	2.85e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—APC—brain cancer	3.78e-06	2.84e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CG—brain cancer	3.78e-06	2.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—ERBB2—brain cancer	3.78e-06	2.83e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CTNNB1—brain cancer	3.78e-06	2.83e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IRS2—brain cancer	3.78e-06	2.83e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—brain cancer	3.75e-06	2.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—MYC—brain cancer	3.75e-06	2.81e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ENO2—brain cancer	3.73e-06	2.8e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CG—brain cancer	3.73e-06	2.8e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—brain cancer	3.72e-06	2.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—STAT3—brain cancer	3.71e-06	2.78e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—brain cancer	3.71e-06	2.78e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HES1—brain cancer	3.7e-06	2.78e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—brain cancer	3.69e-06	2.77e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CTNNB1—brain cancer	3.67e-06	2.75e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—STAT3—brain cancer	3.66e-06	2.74e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—brain cancer	3.64e-06	2.73e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—brain cancer	3.63e-06	2.72e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCND1—brain cancer	3.63e-06	2.72e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—brain cancer	3.61e-06	2.71e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.59e-06	2.69e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CTNNB1—brain cancer	3.59e-06	2.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IRS2—brain cancer	3.58e-06	2.68e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CTNNB1—brain cancer	3.58e-06	2.68e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PDGFRA—brain cancer	3.53e-06	2.64e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ENO2—brain cancer	3.52e-06	2.64e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CTNNB1—brain cancer	3.51e-06	2.63e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CTNNB1—brain cancer	3.49e-06	2.62e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ENO2—brain cancer	3.49e-06	2.62e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—STAT3—brain cancer	3.46e-06	2.6e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—RELA—brain cancer	3.46e-06	2.6e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—brain cancer	3.45e-06	2.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—brain cancer	3.44e-06	2.58e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ERBB2—brain cancer	3.44e-06	2.58e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RELA—brain cancer	3.43e-06	2.57e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SPP1—brain cancer	3.42e-06	2.57e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ERBB2—brain cancer	3.41e-06	2.56e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CG—brain cancer	3.41e-06	2.55e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—APC—brain cancer	3.41e-06	2.55e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BSG—brain cancer	3.38e-06	2.54e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—STAT3—brain cancer	3.38e-06	2.53e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—brain cancer	3.37e-06	2.53e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—APC—brain cancer	3.34e-06	2.5e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CG—brain cancer	3.34e-06	2.5e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—brain cancer	3.33e-06	2.49e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—brain cancer	3.33e-06	2.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CTNNB1—brain cancer	3.32e-06	2.49e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CTNNB1—brain cancer	3.31e-06	2.48e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—RELA—brain cancer	3.3e-06	2.48e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—STAT3—brain cancer	3.29e-06	2.47e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ERBB2—brain cancer	3.28e-06	2.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—STAT3—brain cancer	3.2e-06	2.4e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CG—brain cancer	3.17e-06	2.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—APC—brain cancer	3.16e-06	2.37e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CG—brain cancer	3.16e-06	2.37e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—brain cancer	3.16e-06	2.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—brain cancer	3.15e-06	2.36e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—brain cancer	3.14e-06	2.35e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—STAT3—brain cancer	3.13e-06	2.35e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RELA—brain cancer	3.12e-06	2.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—STAT3—brain cancer	3.12e-06	2.34e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—brain cancer	3.12e-06	2.34e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB2—brain cancer	3.1e-06	2.33e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IRS2—brain cancer	3.1e-06	2.32e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—brain cancer	3.09e-06	2.32e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—brain cancer	3.07e-06	2.3e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—brain cancer	3.06e-06	2.29e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—STAT3—brain cancer	3.06e-06	2.29e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—STAT3—brain cancer	3.04e-06	2.28e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCND1—brain cancer	3.04e-06	2.28e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB2—brain cancer	3.03e-06	2.27e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCND1—brain cancer	3.01e-06	2.26e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CTNNB1—brain cancer	3.01e-06	2.26e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—brain cancer	2.99e-06	2.24e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CTNNB1—brain cancer	2.98e-06	2.24e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—brain cancer	2.98e-06	2.23e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—brain cancer	2.97e-06	2.23e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RELA—brain cancer	2.96e-06	2.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB2—brain cancer	2.94e-06	2.2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—IDH1—brain cancer	2.91e-06	2.18e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—brain cancer	2.91e-06	2.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—brain cancer	2.91e-06	2.18e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—STAT3—brain cancer	2.9e-06	2.17e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—STAT3—brain cancer	2.88e-06	2.16e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CTNNB1—brain cancer	2.87e-06	2.15e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—brain cancer	2.85e-06	2.13e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—brain cancer	2.84e-06	2.13e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—brain cancer	2.81e-06	2.11e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—brain cancer	2.78e-06	2.08e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—brain cancer	2.76e-06	2.07e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—brain cancer	2.74e-06	2.06e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CG—brain cancer	2.73e-06	2.05e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APC—brain cancer	2.73e-06	2.05e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CTNNB1—brain cancer	2.71e-06	2.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—brain cancer	2.68e-06	2.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—brain cancer	2.68e-06	2.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RELA—brain cancer	2.66e-06	2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—brain cancer	2.66e-06	2e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CTNNB1—brain cancer	2.65e-06	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—brain cancer	2.65e-06	1.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB2—brain cancer	2.65e-06	1.98e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—brain cancer	2.63e-06	1.97e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—brain cancer	2.63e-06	1.97e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—brain cancer	2.62e-06	1.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—brain cancer	2.62e-06	1.96e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RELA—brain cancer	2.61e-06	1.95e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—brain cancer	2.6e-06	1.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—brain cancer	2.59e-06	1.95e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB2—brain cancer	2.59e-06	1.94e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—brain cancer	2.57e-06	1.93e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—brain cancer	2.51e-06	1.88e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—brain cancer	2.5e-06	1.88e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RELA—brain cancer	2.47e-06	1.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—brain cancer	2.46e-06	1.84e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—brain cancer	2.44e-06	1.83e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—brain cancer	2.42e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—brain cancer	2.4e-06	1.8e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—brain cancer	2.39e-06	1.79e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—brain cancer	2.39e-06	1.79e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—brain cancer	2.38e-06	1.79e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—brain cancer	2.37e-06	1.77e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—brain cancer	2.36e-06	1.77e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—brain cancer	2.35e-06	1.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—brain cancer	2.34e-06	1.75e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CG—brain cancer	2.32e-06	1.74e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—brain cancer	2.31e-06	1.74e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—brain cancer	2.31e-06	1.73e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO2—brain cancer	2.3e-06	1.72e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—brain cancer	2.29e-06	1.72e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—brain cancer	2.28e-06	1.71e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—brain cancer	2.27e-06	1.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—brain cancer	2.26e-06	1.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—brain cancer	2.24e-06	1.68e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—brain cancer	2.23e-06	1.67e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—brain cancer	2.2e-06	1.65e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—brain cancer	2.17e-06	1.63e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—brain cancer	2.15e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—brain cancer	2.15e-06	1.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—brain cancer	2.15e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RELA—brain cancer	2.14e-06	1.6e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—brain cancer	2.12e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—brain cancer	2.1e-06	1.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—brain cancer	2.08e-06	1.56e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—brain cancer	2.04e-06	1.53e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—brain cancer	2.04e-06	1.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—brain cancer	2.02e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—brain cancer	2e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—brain cancer	2e-06	1.5e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—brain cancer	1.98e-06	1.49e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—brain cancer	1.98e-06	1.48e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—brain cancer	1.97e-06	1.47e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—brain cancer	1.92e-06	1.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—brain cancer	1.89e-06	1.42e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—brain cancer	1.88e-06	1.41e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—brain cancer	1.87e-06	1.41e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—brain cancer	1.87e-06	1.4e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—brain cancer	1.86e-06	1.39e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—brain cancer	1.84e-06	1.38e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—brain cancer	1.83e-06	1.37e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—brain cancer	1.81e-06	1.35e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—brain cancer	1.8e-06	1.35e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—brain cancer	1.74e-06	1.3e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—brain cancer	1.71e-06	1.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—brain cancer	1.71e-06	1.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—brain cancer	1.7e-06	1.28e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—brain cancer	1.64e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—brain cancer	1.62e-06	1.21e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—brain cancer	1.61e-06	1.21e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—brain cancer	1.6e-06	1.2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—brain cancer	1.54e-06	1.15e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—brain cancer	1.51e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—brain cancer	1.5e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—brain cancer	1.47e-06	1.1e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—brain cancer	1.43e-06	1.07e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—brain cancer	1.24e-06	9.26e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—brain cancer	1.06e-06	7.91e-06	CbGpPWpGaD
